Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From UnitedHealth Group

The Booming Business Of Drug Exclusions

The number of drugs included on formulary exclusion lists in the US has surpassed more than 400 at the top three PBMs, representing dramatic growth from just five years ago. Express Scripts recently revealed its 2022 exclusions.

Market Access Reimbursement

ICER Will Explore Link Between Reasonable Drug Pricing And ‘Fair’ US Formulary Policies

Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.

Commercial Market Access

ICER Study On Coverage 'Fairness' Could Inform Manufacturer Pricing vs Benefit Design Debate

Study will look at prior authorization, step therapy and required medication switching for drugs considered to be reasonably priced.

Reimbursement Pricing Debate

The Drugs That Could Face US Generic/Biosimilar Competition In 2021

Other expected generics include Viatris' Perforomist (formoterol fumarate), Pfizer's Sutent (sunitinib), Sanofi's Jevtana (cabazitaxel) and possibly Boehringer Ingelheim's Pradaxa.

Biosimilars Generic Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Services
  • Other Names / Subsidiaries
    • UnitedHealthcare
UsernamePublicRestriction

Register